As cancer treatment with proton therapy is stepping forward into the new era of proton arc therapy (PAT), exciting advancements are on the horizon: IBA together with its clinical partner, Corewell Health’s William Beaumont University Hospital Proton Therapy Center, and industrial partners, Elekta, RaySearch Laboratories and IBA Dosimetry, have taken a significant step for arc proton therapy, moving forward to demonstrate the technical feasibility of DynamicARC* and its ecosystem using the ProteusONE system. These recent tests provide the proof that the unequaled advantages of DynamicARC are within technical reach and bring this innovative treatment approach even closer to Proteus users, enabling a new level of precision and effectiveness to treat cancer patients with proton therapy. In this blog, Dr Rohan Deraniyagala, Medical Director, and Dr. Xuangfeng (Leo) Ding, Lead Proton Physicist, share their excitement for the DynamicARC feasibility and accuracy delivery tests, and its future use for many patient candidates on the ProteusONE system.